Fourth generation fluoroquinolone: new weapon in the arenal of ophthalmic antibiotic

PURPOE: Fourth generation fluoroquinolone (FQ) will oon be introduced to ophthalmology. In thi in vitro tudy, difference in the uceptibility pattern and the potencie of fourth generation FQ (gatifloxacin-GAT and moxifloxacin-MOX) were compared with third generation (levofloxacin-LEV) and econd generation FQ (ciprofloxacin-CIP and ofloxacin-OFX). DEIGN: Experimental laboratory invetigation. METHOD: In retropect, the minimum inhibitory concentration (MIC) of 93 bacterial endophthalmiti iolate were determined to CIP, OFX, LEV, GAT, and MOX uing E-tet. The National Committee of Clinical Laboratory tandard (NCCL) uceptibility pattern and the potencie of the MIC were tatitically compared. REULT: With in vitro tet, taphylococcu aureu iolate that were reitant to CIP and OFX were tatitically mot uceptible (P = .01) to MOX. Coagulae negative taphylococci that were reitant to CIP and OFX were tatitically mot uceptible (P = .02) to MOX and GAT. treptococcu viridan were more uceptible (P = .02) to MOX, GAT, and LEV than CIP and OFX. treptococcu pneumoniae wa leat uceptible (P = .01) to OFX compared with the other FQ. uceptibilitie were equivalent (P = .11) for all other bacterial group. In general, MOX wa the mot potent FQ for gram-poitive bacteria (P = .05) while CIP, MOX, GAT, and LEV demontrated equivalent potencie to gram-negative bacteria. CONCLUION: Thi in vitro tudy indicated that fourth generation FQ appear to cover bacterial reitance to the econd and third generation FQ, were more potent than the econd and third generation FQ for gram-poitive bacteria, and are equally potent for gram-negative bacteria. Clinical tudie will need to confirm thee reult.